A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.

Charlene Compher,Katherine Boothe Levinson,Carolyn L Cambor,Nancy Stoner,Joseph I Boullata,Amanda Piarulli,Bruce Kinosian

JOURNAL OF PARENTERAL AND ENTERAL NUTRITION（2016）

引用 1|浏览6

暂无评分

摘要

Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted in approval of the drug by the Food and Drug Administration in 2012 as a treatment for parenteral nutrition-dependent short bowel syndrome in adults. This report presents the case study of a man with short bowel syndrome caused by portal vein thrombosis who had 4 years exposure to the drug at the time of his death due to cardiovascular disease.

查看译文

关键词

short bowel syndrome,malabsorption,growth factors,glucagon-like peptide 2,teduglutide,cardiovascular

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要